hiv-1

Documents about hiv-1

• A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects#806023ClinicalTrials.gov
• Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients#844131ClinicalTrials.gov
• Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019#849558ClinicalTrials.gov
• Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants#893755ClinicalTrials.gov
• Mosaic HIV-1 Envelope Trimer Immunogens Administered to People Living with HIV (PLWH) in Africa#160188ClinicalTrials.gov
• Bioinformatic Approaches To Investigate Hiv Capsid-Nanobody Interaction#195235İzmir Yüksek Teknoloji Enstitüsü
• PRO 140 by IV Administration in Adults With HIV-1 Infection#890742ClinicalTrials.gov
• A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults#916441ClinicalTrials.gov
• Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects#287377ClinicalTrials.gov
• Metformin and Systemic Inflammation in HIV#343812ClinicalTrials.gov
• HIV, Immune Activation and Salt Sensitive Hypertension#356579ClinicalTrials.gov
• A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers#463758ClinicalTrials.gov
• Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection#828893ClinicalTrials.gov
• Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients#843387ClinicalTrials.gov
• The HIV-2 reservoir: lessons from HIV-1 and knowledge gaps#161367HAL (France)
• HIV-1 genetic diversity and reverse transcriptase resistance mutations in Benin before dolutegravir era, West Africa#214332PLOS
• A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)#830149ClinicalTrials.gov
• Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials#127676ClinicalTrials.gov
• Durvalumab in HIV-1 Patients With Solid Tumors#861547ClinicalTrials.gov
• Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir#918436ClinicalTrials.gov
• Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication#854540ClinicalTrials.gov
• A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules#836046ClinicalTrials.gov
• Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adults#918266ClinicalTrials.gov
• DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)#856290ClinicalTrials.gov
• Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers#995062ClinicalTrials.gov
• A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers#356549ClinicalTrials.gov
• The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine#810511ClinicalTrials.gov
• Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring#837042ClinicalTrials.gov
• 3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption#869735ClinicalTrials.gov
• HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)#856739ClinicalTrials.gov
• A Study of 1592U89 in HIV-Infected Children#865498ClinicalTrials.gov
• Immunogenicity and Safety Trial of the HIV-1 Tat Vaccine#967053ClinicalTrials.gov
• Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery#825054ClinicalTrials.gov
• A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)#838597ClinicalTrials.gov
• GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults#864764ClinicalTrials.gov
• Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)#160161ClinicalTrials.gov
• Investigation of the Interaction and Olgiomerization of Hiv Capsid and Single Domain Antibody as a Biotechnological Drug Against Hiv#195251İzmir Yüksek Teknoloji Enstitüsü
• Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants#804866ClinicalTrials.gov
• A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)#887628ClinicalTrials.gov
• A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects#287404ClinicalTrials.gov
• Biomarkers to Predict Time to Plasma HIV RNA Rebound#859943ClinicalTrials.gov
• A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects#898155ClinicalTrials.gov
• Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients#843799ClinicalTrials.gov
• Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment#994921ClinicalTrials.gov
• Design of soluble HIV-1 Env trimers from highly neutralisation-resistant HIV-1 strains for the isolation of broadly neutralising antibodies#929006WIReDSpace
• New Challenges of HIV-1 Infection: How HIV-1 Attacks and Resides in the Central Nervous System#948820Repositorio de Universidad Autónoma de Chile.
• Transcriptional Analysis of Cervical Epithelial Cell Responses to HIV-1#982859DigitalCommons@University of Nebraska
• A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients#876914ClinicalTrials.gov
• Safety and Effectiveness of a Combination Anti-HIV Drug Treatment#847826ClinicalTrials.gov
• The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients#881286ClinicalTrials.gov